ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
Open Access
- 12 March 2013
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 108 (6), 1238-1244
- https://doi.org/10.1038/bjc.2013.83
Abstract
Excision repair cross-complementation group 1 (ERCC1) expression status has been identified as a candidate marker for predicting efficacy of oxaliplatin (OX) treatment for metastatic colorectal cancer (CRC) in several trials. Also, an association between expression of mismatch repair (MMR) genes and favourable postoperative survival in stage II CRC receiving 5-FU chemotherapy has been identified. It is unknown if the expression of ERCC1 protein and MMR status are associated with survival of stage III colon cancer receiving OX-based chemotherapy. Immunohistochemistry (IHC) analysis of the expression of MMR and ERCC1 was performed on tumour tissue of 255 patients with stage III colon cancer. In all, 95 patients received fluoropyrimidine-based chemotherapy and 160 patients received OX-based chemotherapy. A predictive model for 5-year disease-free survival (DFS) and overall survival (OS) was constructed using Kaplan-Meier analysis, logistic and Cox regression. Patients who were treated with OX-based therapy with positive ERCC1 tumours had lower 5-year DFS (54%) and OS (60%) than those with negative ERCC1 tumours (72% and 78%, respectively; DFS HR: 1.98, 95% confidence interval (CI): 1.19-3.31, P=0.009; OS HR: 2.44, 95% CI: 1.37-4.34, P=0.02). Excision repair cross-complementation group 1 status did not impact DFS or OS in fluorouracil group (DFS HR: 1.16, 95% CI: 0.63-2.14, P=0.62; OS HR: 1.16, 95% CI: 0.63-2.14, P=0.63), whereas MMR status had no impact on DFS or OS in either group. Excision repair cross-complementation group 1 status is highly predictive of which patients will benefit from the addition of OX to 5-FU for stage III colon cancer. Mismatch repair status had no predictive value in this setting.Keywords
This publication has 32 references indexed in Scilit:
- Immunogenic death of colon cancer cells treated with oxaliplatinOncogene, 2009
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3Journal of Clinical Oncology, 2009
- Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803Journal of Clinical Oncology, 2009
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiationBritish Journal of Cancer, 2008
- Molecular Prognostic Markers in Locally Advanced Colon CancerClinical Colorectal Cancer, 2007
- Current status of excision repair cross complementing-group 1 (ERCC1) in cancerCancer Treatment Reviews, 2007
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007
- Molecular mechanisms of resistance and toxicity associated with platinating agentsCancer Treatment Reviews, 2006
- DNA Repair by ERCC1 in Non–Small-Cell Lung Cancer and Cisplatin-Based Adjuvant ChemotherapyNew England Journal of Medicine, 2006